Skip to search formSkip to main contentSkip to account menu

pirfenidone 801 MG Oral Tablet [Esbriet]

Known as: Esbriet 801 MG Oral Tablet, PIRFENIDONE 801 mg ORAL TABLET, COATED [Esbriet] 
National Institutes of Health

Related topics

Related topics

14 relations
Croscarmellose SodiumMagnesium stearateOral TabletPOLYETHYLENE GLYCOL 3350

Broader (1)

pirfenidone Oral Tablet [Esbriet]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
Background Nintedanib (Ofev ® ) and pirfenidone (Esbriet ® ) are recommended by international guidelines as treatment options for… 
2020
2020
Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study
Background In patients with idiopathic pulmonary fibrosis (IPF) treated with pirfenidone (Esbriet®, Genentech USA, Inc. South San… 
2018
2018
[Pirfenidone (Esbriet®): Take care in the sun!]
2017
2017
THE CHANGING ROLE OF THERAPEUTIC ENDOSCOPY IN GASTROENTEROLOGY: IMPROVING PATIENT OUTCOMES
The Ulster Medical Society grants to all users on the basis of a Creative Commons Attribution-NonCommercial-ShareAlike 4.0… 
2016
2016
Pirfenidone in idiopathic pulmonary fibrosis: a guide to its use in the EU
Pirfenidone (Esbriet®), a synthetic pyridine compound with antifibrotic, anti-inflammatory and antioxidant properties that… 
Review
2014
Review
2014
S13 Incidence And Risk Factors For The Development Of Hospital Acquired Pneumonia In Older Hospitalised Patients
Introduction and objectives Older people are at risk of hospital-acquired pneumonia (HAP). Few data exist on the incidence or… 
2012
2012
Pirfenidone: a guide to its use in idiopathic pulmonary fibrosis
In general, oral pirfenidone (Esbriet®) is associated with beneficial effects on forced vital capacity and the 6-minute walk test… 
Review
2012
Review
2012
S98 Early Clinical Experience with Pirfenidone For Idiopathic Pulmonary Fibrosis (IPF) in the UK: Interim Results from a UK Cohort
Introduction and Objectives In March 2011, the novel anti-fibrotic, pirfenidone (Esbriet®), became the first drug to be licenced… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)